Clinical trials: Mania
Bipolar Disorder, Manic
Study of Lumateperone in the Treatment of Patients With Bipolar Mania
This is a multicenter, randomized, double-blind, placebo-controlled, study in the acute treatment of patients with a diagnosis of bipolar I disorder with manic episodes or manic episodes with mixed features (bipolar mania), with…
- Trial name
- NCT06462612
- Testing
- Lumateperone
- Where
- 35 sites in United States, Bulgaria and 2 more
- Volunteers
- 351 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Acute Bipolar Mania
A Comparison of the Effectiveness of Seroquel XR and Seroquel XR Plus Lithium in Patients With Acute Bipolar Mania: An Open-label, Randomized, Parallel Groups, Rater-blinded, 4 Week, Multicenter, Comparative,Study
The primary objective of this study is to compare the efficacy of Seroquel XR monotherapy compared with Seroquel XR plus lithium in the treatment of acute bipolar mania by evaluation of the changes from baseline in Young Mania…
- Trial name
- STAR (NCT01254721)
- Testing
- Quetiapine fumarate, lithium
- Where
- 5 sites in South Korea
- Volunteers
- 131 people
- Sponsor
- AstraZeneca
Acute Mania in Bipolar Disorder
Quetiapine Fumarate (Seroquel) as Mono-Therapy or Adjunct to Lithium in the Treatment of Patients With Acute Mania in Bipolar Disorder
To compare the efficacy and safety of quetiapine fumarate given as mono-therapy or adjunct therapy to lithium in the treatment of patients with acute mania in bipolar disorder.
- Trial name
- MANIA (NCT00672490)
- Testing
- Quetiapine Fumarate, Lithium
- Where
- 16 sites in China
- Volunteers
- 376 people
- Sponsor
- AstraZeneca
Bipolar 1 Disorder
Fixed-dose Safety and Efficacy Study of Asenapine for the Treatment of Acute Manic or Mixed Episode in Bipolar 1 Disorder (P05691)
This trial will study the efficacy and safety of a fixed dose of asenapine in participants diagnosed with Bipolar 1 Disorder. Participants who qualify for the study will be randomly assigned to receive a fixed dose of asenapine…
- Trial name
- NCT00764478
- Testing
- Asenapine
- Volunteers
- 367 people
- Sponsor
- Organon and Co
Bipolar Disorder
Trial of Olanzapine in Patients With Manic or Mixed Episode of Bipolar I Disorder
The purpose of this study is to confirm the efficacy of olanzapine in the treatment of manic or mixed symptoms associated with bipolar I disorder.
- Trial name
- NCT00129220
- Testing
- olanzapine, haloperidol
- Where
- 16 sites in Japan
- Volunteers
- 224 people
- Sponsor
- Eli Lilly and Company
Bipolar Disorder, Manic
Study of Lumateperone in the Acute Treatment of Patients With Bipolar Mania
This is a multicenter, randomized, double-blind, placebo-controlled, study in the acute treatment of patients with a diagnosis of bipolar I disorder with manic episodes or manic episodes with mixed features (bipolar mania), with…
- Trial name
- NCT06462586
- Testing
- Lumateperone
- Where
- 42 sites in United States, Bulgaria and 3 more
- Volunteers
- 354 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Bipolar Disorder
Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder
The purpose of this study is to evaluate the effectiveness and tolerability of an investigational drug for the treatment of manic episodes of bipolar disorder.
- Trial name
- NCT00107926
- Testing
- Licarbazepine
- Where
- 44 sites in United States, Austria and 11 more
- Volunteers
- 343 people
- Sponsor
- Novartis Pharmaceuticals
Bipolar Disorder
Depressive Symptoms in Acute Manic Episode
Observational, non-interventional, transversal, multicenter, open label (No treatment is involved). The primary objective is to detect the prevalence of depressive symptoms in bipolar patients admitted to a psychiatric Unit due…
- Trial name
- MM1 (NCT00690248)
- Where
- 34 sites in Spain
- Volunteers
- 250 people
- Sponsor
- AstraZeneca
Bipolar Disorder, Pediatric
Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder (P06107 Has an Extension [P05898; NCT01349907])(P06107)
Efficacy and safety of asenapine for the treatment of bipolar I disorder (manic or mixed episodes) will be evaluated in participants between 10 and 17 years old, who are either hospitalized or non-hospitalized.
- Trial name
- NCT01244815
- Testing
- asenapine, Rescue medication
- Volunteers
- 404 people
- Sponsor
- Organon and Co
Bipolar Disorder, New Occurred Episode
Management of Index Episode in Patients With Bipolar Disorder Treated by Seroquel XR
The primary purpose of the study is to explore management of symptomatology in patients with bipolar disorder that experience a new manic,depressive or mixed episode and are treated with Seroquel XR monotherapy/adjuctive, in…
- Trial name
- NCT01029145
- Where
- 30 sites in Romania
- Volunteers
- 537 people
- Sponsor
- AstraZeneca
Bipolar I Disorder
An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder.
This extension study is designed to investigate the long-term safety and tolerability of licarbazepine 750-2000 mg/day over 52 weeks in patients who completed the 3-week double-blind study CLIC477D2301.
- Trial name
- NCT00228059
- Testing
- Licarbazepine
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- Novartis
Bipolar Disorder With Manic or Mixed Episodes
Safety and Efficacy of MEM 1003 Versus Placebo for the Treatment of Patients With Bipolar I Disorder
The purpose of this study is to establish the potential of MEM 1003 as a safe and effective treatment for patients with an acute manic or mixed episode of bipolar disorder.
- Trial name
- NCT00374920
- Testing
- MEM 1003
- Where
- 21 sites in United States
- Volunteers
- 60 people
- Sponsor
- Memory Pharmaceuticals
Psychotic Disorders, Schizophrenia
FAST-A Study to Evaluate the Efficacy and Safety of Quetiapin IR in Patients With Acute Psychosis
The purpose of this study is to compare the efficacy of quetiapine IR, following rapid titration versus conventional titration in patients with acute psychosis
- Conditions
- Psychotic Disorders, Schizophrenia, Bipolar Disorder
- Trial name
- FAST (NCT00486798)
- Testing
- Quetiapine, Rating Scales, Self Assessment Form
- Where
- 13 sites in Sweden
- Sponsor
- AstraZeneca
Bipolar Disorder
Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder
This 26-week open-label extension study is designed to provide information on the safety and tolerability of oral ziprasidone (20-80 mg BID (twice daily) with meals) during long-term administration in children and adolescents…
- Trial name
- NCT03768726
- Testing
- Ziprasidone
- Where
- 9 sites in United States
- Volunteers
- 23 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Bipolar Disorder, Mood Disorders
A Study to Evaluate the Efficacy and Safety of Flexible Doses of Extended-release (ER) Paliperidone Compared With Flexible Doses of Quetiapine and Placebo in Patients With Bipolar I Disorder
The purpose of this study is to evaluate the effectiveness and safety of flexible-doses paliperidone ER (3 to 12 mg as needed) compared with placebo over 3 weeks in patients with Bipolar I Disorder who are experiencing an acute…
- Trial name
- NCT00309699
- Testing
- Quetiapine, Paliperidone ER
- Where
- 47 sites in United States, Greece and 6 more
- Volunteers
- 493 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Bipolar I Disorder
An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750-2000 mg/d in the Treatment of Manic Episodes of Bipolar I Disorder
This extension study is designed to investigate the long-term safety and tolerability of licarbazepine 750-2000 mg/d over 52 weeks in patients who completed the 6-week double-blind study CLIC477D2302.
- Trial name
- NCT00238485
- Testing
- Licarbazepine
- Volunteers
- 251 people
- Sponsor
- Novartis
Bipolar Disorder
Optimal Length of Treatment Continuation With Olanzapine After Remission of Manic or Mixed Episode
This is a randomized, parallel, open-label study of patients who have responded to treatment in the acute phase of their manic or mixed episode, with or without psychotic symptoms, with olanzapine in mono or co-therapy, and who…
- Trial name
- NCT00191997
- Testing
- Olanzapine
- Where
- 11 sites in Spain
- Volunteers
- 180 people
- Sponsor
- Eli Lilly and Company
Bipolar Disorder
The Safety and Efficacy of Risperidone as Adjunctive Therapy to Mood Stabilizers in the Long-term Treatment of Bipolar Mania
The purpose of this study is to evaluate effect of risperidone as a long-term combination therapy to mood stabilizers in the treatment of bipolar mania
- Trial name
- NCT00216554
- Testing
- risperidone
- Volunteers
- 118 people
- Sponsor
- Janssen Korea, Ltd., Korea
Bipolar Disorder, Mania
Safety and Efficacy Study of Lithium in Bipolar Disorder
The purpose of this study is to determine whether Lithium is safe and effective in the treatment of Bipolar I Disorder subjects with symptoms of acute mania.
- Trial name
- NCT00422331
- Testing
- Lithium Carbonate Capsule
- Where
- United States
- Volunteers
- 206 people
- Sponsor
- JDS Pharmaceuticals
Bipolar Disorder
Study of Aripiprazole in Patients With Acute Bipolar Mania
The purpose of this research study is to confirm the safety and effectiveness of aripiprazole therapy over 12 weeks in subjects with bipolar disorder experiencing symptoms of mania.
- Trial name
- NCT00097266
- Testing
- Aripiprazole, Haloperidol
- Where
- 45 sites in United States, Bulgaria and 5 more
- Volunteers
- 615 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.